The role of leukotriene B4 in allergic diseases

Hiroshi Ohnishi, Nobuaki Miyahara, Erwin W. Gelfand

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Leukotriene B4 (LTB4) is a lipid mediator with potent chemoattractant properties and that is rapidly generated from activated innate immune cells such as neutrophils, macrophages, and mast cells. Elevated levels of LTB4 have been reported in various allergic diseases and these levels have been related to disease activity and response to treatment. Recent studies using LTB4 receptor-1 (BLT1) antagonists or BLT1-deficient mice have revealed that ligation of BLT1 by LTB4 is important for the activation and recruitment of inflammatory cells including neutrophils, eosinophils, imonocytes/macrophages, mast cells, dendritic cells, and more recently, effector T cells to inflamed tissues in various inflammatory diseases. The LTB4/BLT1 pathway appears to play an important role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and chemokines. LTB4 production is in general resistant to corticosteroid treatment. In fact, corticosteroids can upregulate BLT1 expression on corticosteroid-resistant inflammatory cells such as neutrophils, monocytes, and effector memory CD8+ T cells. As a result, this corticosteroid-resistant LTB4/BLT1 pathway may contribute to the development of inflammation in allergic diseases that do not respond to the introduction of corticosteroids. Inhibition of this pathway has potential therapeutic benefit in various allergic diseases that have involvement of corticosteroid-insensitivity.

Original languageEnglish
Pages (from-to)291-298
Number of pages8
JournalAllergology International
Volume57
Issue number4
DOIs
Publication statusPublished - 2008

Fingerprint

Leukotriene B4
Adrenal Cortex Hormones
Neutrophils
Mast Cells
Aspirin Induced Asthma
Leukotriene B4 Receptors
Macrophages
Exercise-Induced Asthma
T-Lymphocytes
Chemotactic Factors
Atopic Dermatitis
Chemokines
Eosinophils
Dendritic Cells
Ligation
Monocytes
Up-Regulation
Asthma
Cytokines
Inflammation

Keywords

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Asthma
  • Atopic dermatitis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The role of leukotriene B4 in allergic diseases. / Ohnishi, Hiroshi; Miyahara, Nobuaki; Gelfand, Erwin W.

In: Allergology International, Vol. 57, No. 4, 2008, p. 291-298.

Research output: Contribution to journalArticle

Ohnishi, Hiroshi ; Miyahara, Nobuaki ; Gelfand, Erwin W. / The role of leukotriene B4 in allergic diseases. In: Allergology International. 2008 ; Vol. 57, No. 4. pp. 291-298.
@article{c049c8904163471686bba11df0e9064c,
title = "The role of leukotriene B4 in allergic diseases",
abstract = "Leukotriene B4 (LTB4) is a lipid mediator with potent chemoattractant properties and that is rapidly generated from activated innate immune cells such as neutrophils, macrophages, and mast cells. Elevated levels of LTB4 have been reported in various allergic diseases and these levels have been related to disease activity and response to treatment. Recent studies using LTB4 receptor-1 (BLT1) antagonists or BLT1-deficient mice have revealed that ligation of BLT1 by LTB4 is important for the activation and recruitment of inflammatory cells including neutrophils, eosinophils, imonocytes/macrophages, mast cells, dendritic cells, and more recently, effector T cells to inflamed tissues in various inflammatory diseases. The LTB4/BLT1 pathway appears to play an important role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and chemokines. LTB4 production is in general resistant to corticosteroid treatment. In fact, corticosteroids can upregulate BLT1 expression on corticosteroid-resistant inflammatory cells such as neutrophils, monocytes, and effector memory CD8+ T cells. As a result, this corticosteroid-resistant LTB4/BLT1 pathway may contribute to the development of inflammation in allergic diseases that do not respond to the introduction of corticosteroids. Inhibition of this pathway has potential therapeutic benefit in various allergic diseases that have involvement of corticosteroid-insensitivity.",
keywords = "Allergic conjunctivitis, Allergic rhinitis, Asthma, Atopic dermatitis",
author = "Hiroshi Ohnishi and Nobuaki Miyahara and Gelfand, {Erwin W.}",
year = "2008",
doi = "10.2332/allergolint.08-RAI-0019",
language = "English",
volume = "57",
pages = "291--298",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "4",

}

TY - JOUR

T1 - The role of leukotriene B4 in allergic diseases

AU - Ohnishi, Hiroshi

AU - Miyahara, Nobuaki

AU - Gelfand, Erwin W.

PY - 2008

Y1 - 2008

N2 - Leukotriene B4 (LTB4) is a lipid mediator with potent chemoattractant properties and that is rapidly generated from activated innate immune cells such as neutrophils, macrophages, and mast cells. Elevated levels of LTB4 have been reported in various allergic diseases and these levels have been related to disease activity and response to treatment. Recent studies using LTB4 receptor-1 (BLT1) antagonists or BLT1-deficient mice have revealed that ligation of BLT1 by LTB4 is important for the activation and recruitment of inflammatory cells including neutrophils, eosinophils, imonocytes/macrophages, mast cells, dendritic cells, and more recently, effector T cells to inflamed tissues in various inflammatory diseases. The LTB4/BLT1 pathway appears to play an important role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and chemokines. LTB4 production is in general resistant to corticosteroid treatment. In fact, corticosteroids can upregulate BLT1 expression on corticosteroid-resistant inflammatory cells such as neutrophils, monocytes, and effector memory CD8+ T cells. As a result, this corticosteroid-resistant LTB4/BLT1 pathway may contribute to the development of inflammation in allergic diseases that do not respond to the introduction of corticosteroids. Inhibition of this pathway has potential therapeutic benefit in various allergic diseases that have involvement of corticosteroid-insensitivity.

AB - Leukotriene B4 (LTB4) is a lipid mediator with potent chemoattractant properties and that is rapidly generated from activated innate immune cells such as neutrophils, macrophages, and mast cells. Elevated levels of LTB4 have been reported in various allergic diseases and these levels have been related to disease activity and response to treatment. Recent studies using LTB4 receptor-1 (BLT1) antagonists or BLT1-deficient mice have revealed that ligation of BLT1 by LTB4 is important for the activation and recruitment of inflammatory cells including neutrophils, eosinophils, imonocytes/macrophages, mast cells, dendritic cells, and more recently, effector T cells to inflamed tissues in various inflammatory diseases. The LTB4/BLT1 pathway appears to play an important role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and chemokines. LTB4 production is in general resistant to corticosteroid treatment. In fact, corticosteroids can upregulate BLT1 expression on corticosteroid-resistant inflammatory cells such as neutrophils, monocytes, and effector memory CD8+ T cells. As a result, this corticosteroid-resistant LTB4/BLT1 pathway may contribute to the development of inflammation in allergic diseases that do not respond to the introduction of corticosteroids. Inhibition of this pathway has potential therapeutic benefit in various allergic diseases that have involvement of corticosteroid-insensitivity.

KW - Allergic conjunctivitis

KW - Allergic rhinitis

KW - Asthma

KW - Atopic dermatitis

UR - http://www.scopus.com/inward/record.url?scp=59549104762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59549104762&partnerID=8YFLogxK

U2 - 10.2332/allergolint.08-RAI-0019

DO - 10.2332/allergolint.08-RAI-0019

M3 - Article

VL - 57

SP - 291

EP - 298

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 4

ER -